SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Sean McCarthy to moderate panel, "Bridges Over Troubled Water and M&A "a la carte": Financing and Exiting", at Bio 2010 in Chicago, IL
News | 05. 05. 2010
